ADAPY

SEC source: 0001104659-21-112179 · tm2126797-1_4seq1.xml · nonDerivative · entry 1

Rawcliffe Adrian · CIK 0001555851 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,070

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on September 1, 2019 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $5.18 to $5.225, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 45,447 ADSs and RSU-style options and other options covering an aggregate of 16,461,144 ordinary shares of the Issuer.

SEC source: 0001104659-21-098959 · tm2121284-10_4seq1.xml · nonDerivative · entry 1

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,873

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on August 1, 2019 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.56 to $3.60, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 30,268 ADSs and RSU-style options and other options covering an aggregate of 4,746,084 ordinary shares of the Issuer.

SEC source: 0001104659-21-089050 · tm2121284-9_4seq1.xml · nonDerivative · entry 1

Bertrand William C JR · CIK 0001291937 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,329

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 16, 2020 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $4.26 to $4.30, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 57,100 ADSs and RSU-style options and other options covering an aggregate of 8,005,428 ordinary shares of the Issuer.

SEC source: 0001104659-21-089048 · tm2121284-8_4seq1.xml · nonDerivative · entry 1

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,170

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on July 2, 2018 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $4.26 to $4.30, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 27,098 ADSs and RSU-style options and other options covering an aggregate of 4,792,956 ordinary shares of the Issuer.

SEC source: 0001104659-21-088971 · tm2121284-5_4seq1.xml · derivative · entry 1

Furey John · CIK 0001691218 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 379,788

Underlying: Ordinary Shares · 379,788 shares

Expires 2031-07-01

F1 · derivative.exercise_price: The exercise price was converted from GBP0.51 based on an exchange rate of $U.S. 1.3807 to GBP1.00. The actual exercise price will be the pounds sterling amount.

SEC source: 0001104659-21-088974 · tm2121284-7_4seq1.xml · derivative · entry 1

Zaks Tal Zvi · CIK 0001690927 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 379,788

Underlying: Ordinary Shares · 379,788 shares

Expires 2031-07-01

F1 · derivative.exercise_price: The exercise price was converted from GBP0.51 based on an exchange rate of $U.S. 1.3807 to GBP1.00. The actual exercise price will be the pounds sterling amount.

SEC source: 0001104659-21-088960 · tm2121284-1_4seq1.xml · derivative · entry 1

Duncan Barbara Gayle · CIK 0001353128 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 379,788

Underlying: Ordinary Shares · 379,788 shares

Expires 2031-07-01

F1 · derivative.exercise_price: The exercise price was converted from GBP0.51 based on an exchange rate of $U.S. 1.3807 to GBP1.00. The actual exercise price will be the pounds sterling amount.

SEC source: 0001104659-21-088965 · tm2121284-2_4seq1.xml · derivative · entry 1

MOTT DAVID M · CIK 0001219871 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 579,494

Underlying: Ordinary Shares · 579,494 shares

Expires 2031-07-01

F1 · derivative.exercise_price: The exercise price was converted from GBP0.51 based on an exchange rate of $U.S. 1.3807 to GBP1.00. The actual exercise price will be the pounds sterling amount

SEC source: 0001104659-21-088969 · tm2121284-4_4seq1.xml · derivative · entry 1

Noble James · CIK 0001388000 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 379,788

Underlying: Ordinary Shares · 379,788 shares

Expires 2031-07-01

F1 · derivative.exercise_price: The exercise price was converted from GBP0.51 based on an exchange rate of $U.S. 1.3807 to GBP1.00. The actual exercise price will be the pounds sterling amount.

SEC source: 0001104659-21-088972 · tm2121284-6_4seq1.xml · derivative · entry 1

Alleva Lawrence M · CIK 0001553053 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 505,918

Underlying: Ordinary Shares · 505,918 shares

Expires 2031-07-01

F1 · derivative.exercise_price: The exercise price was converted from GBP0.51 based on an exchange rate of $U.S. 1.3807 to GBP1.00. The actual exercise price will be the pounds sterling amount.

SEC source: 0001209191-21-045059 · doc4.xml · derivative · entry 1

Behbahani Ali · CIK 0001613867 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 474,385

Underlying: Ordinary Shares · 474,385 shares

Expires 2031-07-01

F1 · derivative.exercise_price: The exercise price was converted from GBP0.51 based on an exchange rate of $U.S. 1.3807 to GBP1.00. The actual exercise price will be the pounds sterling amount.

SEC source: 0001104659-21-088967 · tm2121284-3_4seq1.xml · derivative · entry 1

Sigal Charles Elliott · CIK 0001661908 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 474,385

Underlying: Ordinary Shares · 474,385 shares

Expires 2031-07-02

F1 · derivative.exercise_price: The exercise price was converted from GBP0.51 based on an exchange rate of $U.S. 1.3807 to GBP1.00. The actual exercise price will be the pounds sterling amount.

SEC source: 0001104659-21-086385 · tm2118429-2_4seq1.xml · nonDerivative · entry 1

Rawcliffe Adrian · CIK 0001555851 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,058

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on June 27, 2019 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is the sale price per ADS.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 42,389 ADSs and RSU-style options and other options covering an aggregate of 16,461,144 ordinary shares of the Issuer.

SEC source: 0001104659-21-076401 · tm2118429-1_4seq1.xml · nonDerivative · entry 1

Alleva Lawrence M · CIK 0001553053 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by Trust

Disclosed balance after: 12,600

F1 · security: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADS") and are held in the form of ADSs by the Lawrence M. Alleva Revocable Trust. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc.

F2 · shares: The 12,600 ordinary shares reported in Column 4 and Column 5 are represented by 2,100 ADSs.

F3 · price: The price reported in Column 4 of $0.79 per ordinary share is derived from the weighted average purchase price paid on June 1, 2021 of $4.745 per ADS divided by six.

F2 · balance_after: The 12,600 ordinary shares reported in Column 4 and Column 5 are represented by 2,100 ADSs.

SEC source: 0001104659-21-031733 · tm218630-1_4seq1.xml · nonDerivative · entry 1

TAYTON-MARTIN HELEN KATRINA · CIK 0001661780 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,800,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The ordinary shares whose purchase is reported on this line were obtained from the exercise of share options that were granted on March 20, 2015. The ordinary shares continue to be held by the Reporting Person.

F2 · price: The price reported in Column 4 of $0.157 per ordinary share is derived from the option purchase price paid on March 3, 2021 of GBP0.112 per ordinary share.

F3 · balance_after: The 1,800,000 ordinary shares reported in Column 5 include 1,785,000 ordinary shares reported in Column 4 as well as 15,000 ordinary shares held by the Reporting Person. The ordinary shares reported in Column 5 represent solely the ordinary shares beneficially owned by the Reporting Person. Additionally, the Reporting Person holds options covering an aggregate of 9,703,672 ordinary shares of the Issuer. Ordinary shares may be represented by American Depositary Shares (ADSs) with each ADS representing six ordinary shares.

SEC source: 0001104659-21-005544 · tm213569-1_4seq1.xml · nonDerivative · entry 1

Rawcliffe Adrian · CIK 0001555851 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,529

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 16, 2020 and which vested on January 16, 2021. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $5.64 to $5.72, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 28,860 ADSs and RSU-style options and other options covering an aggregate of 16,531,368 ordinary shares of the Issuer.

SEC source: 0001104659-21-005545 · tm213569-2_4seq1.xml · nonDerivative · entry 1

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,346

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 16, 2020 and which vested on January 16, 2021. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $5.64 to $5.72, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 19,752 ADSs and RSU-style options and other options covering an aggregate of 4,823,418 ordinary shares of the Issuer.

SEC source: 0001104659-21-005546 · tm213569-3_4.xml · nonDerivative · entry 1

Norry Elliot · CIK 0001798117 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,539

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 16, 2020 and which vested on January 16, 2021. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $5.64 to $5.72, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 6,793 ADSs and RSU-style options and other options covering an aggregate of 2,395,766 ordinary shares of the Issuer.

SEC source: 0001104659-21-003594 · tm212950-4_4seq1.xml · nonDerivative · entry 1

Bertrand William C JR · CIK 0001291937 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,768

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2018 and which vested on January 12, 2021. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $6.15 to $6.22, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 53,332 ADSs and RSU-style options and other options covering an aggregate of 8,075,652 ordinary shares of the Issuer.

SEC source: 0001104659-21-003590 · tm212950-1_4seq1.xml · nonDerivative · entry 1

Rawcliffe Adrian · CIK 0001555851 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,695

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2018 and which vested on January 12, 2021. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $6.15 to $6.22, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 25,165 ADSs and RSU-style options and other options covering an aggregate of 16,671,816 ordinary shares of the Issuer.

SEC source: 0001104659-21-003592 · tm212950-3_4seq1.xml · nonDerivative · entry 1

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,767

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2018 and which vested on January 12, 2021. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $6.15 to $6.22, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 17,985 ADSs and RSU-style options and other options covering an aggregate of 4,893,642 ordinary shares of the Issuer.

SEC source: 0001104659-21-003591 · tm212950-2_4seq1.xml · nonDerivative · entry 1

Norry Elliot · CIK 0001798117 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,396

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2018 and which vested on January 12, 2021. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $6.15 to $6.22, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 5,397 ADSs and RSU-style options and other options covering an aggregate of 2,429,666 ordinary shares of the Issuer.

SEC source: 0001104659-21-003129 · tm212800-1_4seq1.xml · derivative · entry 2

Bertrand William C JR · CIK 0001291937 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 242,712

Underlying: Ordinary Shares · 242,712 shares

Expires not disclosed

F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.358422 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Exercisable as to 60,678 Ordinary Shares on January 11, 2022 and will be exercisable as to the remainder in annual installments of 60,678 Ordinary Shares on the eleventh of each January from January 11, 2023 through January 11, 2025.

F5 · derivative.expiration_date: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.

SEC source: 0001104659-21-003129 · tm212800-1_4seq1.xml · derivative · entry 1

Bertrand William C JR · CIK 0001291937 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,086,816

Underlying: Ordinary Shares · 1,086,816 shares

Expires 2031-01-11

F1 · derivative.exercise_price: The exercise price was converted from GBP0.76 based on an exchange rate of U.S.$ 1.358422 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F2 · derivative.exercise_date: Exercisable as to 271,704 Ordinary Shares on January 11, 2022 and will be exercisable as to the remainder in monthly installments of 22,638 Ordinary Shares on the eleventh of each month from February 11, 2022 through December 11, 2024 and 22,782 Ordinary Shares on January 11, 2025.

SEC source: 0001104659-21-003132 · tm212800-4_4seq1.xml · derivative · entry 2

Rawcliffe Adrian · CIK 0001555851 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 728,160

Underlying: Ordinary Shares · 728,160 shares

Expires not disclosed

F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.358422 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Exercisable as to 182,040 Ordinary Shares on January 11, 2022 and will be exercisable as to the remainder in annual installments of 182,040 Ordinary Shares on the eleventh of each January from January 11, 2023 through January 11, 2025.

F5 · derivative.expiration_date: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.

SEC source: 0001104659-21-003132 · tm212800-4_4seq1.xml · derivative · entry 1

Rawcliffe Adrian · CIK 0001555851 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,260,400

Underlying: Ordinary Shares · 3,260,400 shares

Expires 2031-01-11

F1 · derivative.exercise_price: The exercise price was converted from GBP0.76 based on an exchange rate of $U.S. 1.358422 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F2 · derivative.exercise_date: Exercisable as to 815,100 Ordinary Shares on January 11, 2022 and will be exercisable as to the remainder in monthly installments of 67,920 Ordinary Shares on the eleventh of each month from February 11, 2022 through December 11, 2024 and 68,100 Ordinary Shares on January 11, 2025.

SEC source: 0001104659-21-003134 · tm212800-6_4seq1.xml · derivative · entry 2

Wood Gavin · CIK 0001577539 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 242,712

Underlying: Ordinary Shares · 242,712 shares

Expires 2031-01-11

F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.358422 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Exercisable as to 60,678 Ordinary Shares on January 11, 2022 and will be exercisable as to the remainder in annual installments of 60,678 Ordinary Shares on the eleventh of each January from January 11, 2023 through January 11, 2025.

SEC source: 0001104659-21-003134 · tm212800-6_4seq1.xml · derivative · entry 1

Wood Gavin · CIK 0001577539 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,086,816

Underlying: Ordinary Shares · 1,086,816 shares

Expires 2031-01-11

F1 · derivative.exercise_price: The exercise price was converted from GBP0.76 based on an exchange rate of U.S.$ 1.358422 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F2 · derivative.exercise_date: Exercisable as to 271,704 Ordinary Shares on January 11, 2022 and will be exercisable as to the remainder in monthly installments of 22,638 Ordinary Shares on the eleventh of each month from February 11, 2022 through December 11, 2024 and 22,782 Ordinary Shares on January 11, 2025.

SEC source: 0001104659-21-003133 · tm212800-5_4seq1.xml · derivative · entry 2

Norry Elliot · CIK 0001798117 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 242,712

Underlying: Ordinary Shares · 242,712 shares

Expires not disclosed

F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.358422 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Exercisable as to 60,678 Ordinary Shares on January 11, 2022 and will be exercisable as to the remainder in annual installments of 60,678 Ordinary Shares on the eleventh of each January from January 11, 2023 through January 11, 2025.

F5 · derivative.expiration_date: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.

SEC source: 0001104659-21-003133 · tm212800-5_4seq1.xml · derivative · entry 1

Norry Elliot · CIK 0001798117 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,086,816

Underlying: Ordinary Shares · 1,086,816 shares

Expires 2031-01-11

F1 · derivative.exercise_price: The exercise price was converted from GBP0.76 based on an exchange rate of $U.S. 1.358422 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F2 · derivative.exercise_date: Exercisable as to 271,704 Ordinary Shares on January 11, 2022 and will be exercisable as to the remainder in monthly installments of 22,638 Ordinary Shares on the eleventh of each month from February 11, 2022 through December 11, 2024 and 22,782 Ordinary Shares on January 11, 2025.

SEC source: 0001104659-21-003131 · tm212800-3_4seq1.xml · derivative · entry 2

TAYTON-MARTIN HELEN KATRINA · CIK 0001661780 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 242,712

Underlying: Ordinary Shares · 242,712 shares

Expires 2031-01-11

F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.358422 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Exercisable as to 60,678 Ordinary Shares on January 11, 2022 and will be exercisable as to the remainder in annual installments of 60,678 Ordinary Shares on January 11, 2023 and January 11, 2024, and 60,678 Ordinary Shares on January 11, 2025.

SEC source: 0001104659-21-003131 · tm212800-3_4seq1.xml · derivative · entry 1

TAYTON-MARTIN HELEN KATRINA · CIK 0001661780 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,086,816

Underlying: Ordinary Shares · 1,086,816 shares

Expires 2031-01-11

F1 · derivative.exercise_price: The exercise price was converted from GBP0.76 based on an exchange rate of U.S. $1.358422 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F2 · derivative.exercise_date: Exercisable as to 271,704 Ordinary Shares on January 11, 2022 and will be exercisable as to the remainder in monthly installments of 22,638 Ordinary Shares on the eleventh of each month from February 11, 2022 through December 11, 2024 and 22,782 Ordinary Shares on January 11, 2025.

SEC source: 0001104659-21-003130 · tm212800-2_4seq1.xml · derivative · entry 2

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 242,712

Underlying: Ordinary Shares · 242,712 shares

Expires not disclosed

F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.358422 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Exercisable as to 60,678 Ordinary Shares on January 11, 2022 and will be exercisable as to the remainder in annual installments of 60,678 Ordinary Shares on the eleventh of each January from January 11, 2023 through January 11, 2025.

F5 · derivative.expiration_date: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.

SEC source: 0001104659-21-003130 · tm212800-2_4seq1.xml · derivative · entry 1

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,086,816

Underlying: Ordinary Shares · 1,086,816 shares

Expires 2031-01-11

F1 · derivative.exercise_price: The exercise price was converted from GBP0.76 based on an exchange rate of U.S.$ 1.358422 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F2 · derivative.exercise_date: Exercisable as to 271,704 Ordinary Shares on January 11, 2022 and will be exercisable as to the remainder in monthly installments of 22,638 Ordinary Shares on the eleventh of each month from February 11, 2022 through December 11, 2024 and 22,782 Ordinary Shares on January 11, 2025.

SEC source: 0001104659-21-001177 · tm211506-3_4seq1.xml · nonDerivative · entry 1

Bertrand William C JR · CIK 0001291937 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,864

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 4, 2019 and which vested on January 4, 2021. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $5.265 to $5.45, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 47,468 ADSs and RSU-style options and other options covering an aggregate of 6,782,136 ordinary shares of the Issuer.

SEC source: 0001104659-21-001175 · tm211506-1_4seq1.xml · nonDerivative · entry 1

Rawcliffe Adrian · CIK 0001555851 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,737

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 4, 2019 and which vested on January 4, 2021. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $5.265 to $5.45, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 18,428 ADSs and RSU-style options and other options covering an aggregate of 12,721,668 ordinary shares of the Issuer.

SEC source: 0001104659-21-001178 · tm211506d4_4seq1.xml · nonDerivative · entry 1

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,760

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 4, 2019 and which vested on January 4, 2021. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $5.265 to $5.45, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 16,225 ADSs and RSU-style options and other options covering an aggregate of 3,581,064 ordinary shares of the Issuer.

SEC source: 0001104659-21-001176 · tm211506-2_4seq1.xml · nonDerivative · entry 1

Norry Elliot · CIK 0001798117 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,392

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 4, 2019 and which vested on January 4, 2021. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $5.265 to $5.45, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 4,005 ADSs and RSU-style options and other options covering an aggregate of 1,113,560 ordinary shares of the Issuer.

SEC source: 0001104659-20-135891 · tm2038497-1_4.xml · nonDerivative · entry 1

Bertrand William C JR · CIK 0001291937 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 284,808

F1 · security: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADS") and are held in the form of ADSs by William Bertrand. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc.

F2 · shares: The 207,000 ordinary shares reported in Column 4 are represented by 34,500 ADSs.

F3 · price: The price reported in Column 4 of $0.6948 per ordinary share is derived from the purchase price paid on December 14, 2020 of $4.1688 per ADS divided by six. The purchase price per ADS is a weighted average price. These ADSs were purchased in multiple transactions at prices ranging from $4.14 to $4.17, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs purchased at each separate price within the range set forth in this footnote.

F4 · balance_after: The 284,808 ordinary shares reported in Column 5 include 77,808 ordinary shares represented by 12,968 ADSs owned by Mr. Bertrand prior to the purchase reported in Column 4. These shares are held in the form of ADSs by Mr. Bertrand.

SEC source: 0001104659-20-136481 · tm2038497-2_4seq1.xml · nonDerivative · entry 1

Wood Gavin · CIK 0001577539 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,000

F1 · security: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADS") and are held in the form of ADSs by Gavin Wood. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc.

F2 · shares: The 24,000 ordinary shares reported in Column 4 are represented by 4,000 ADSs.

F3 · price: The price reported in Column 4 of $0.6896 per ordinary share is derived from the purchase price paid on December 14, 2020 of $4.1375 per ADS divided by six.

F4 · balance_after: The 57,000 ordinary shares reported in Column 5 include 33,000 ordinary shares represented by 5,500 ADSs owned by Mr. Wood prior to the purchase reported in Column 4. These shares are held in the form of ADSs by Mr. Wood.

SEC source: 0001104659-20-101976 · a4.xml · nonDerivative · entry 1

Rawcliffe Adrian · CIK 0001555851 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,076

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on September 1, 2019 and which vested on September 1, 2020. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price based on prices ranging from $8.505 to $8.635, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 15,352 ADSs and RSU-style options and other options covering an aggregate of 12,791,892 ordinary shares of the Issuer.

SEC source: 0001104659-20-090468 · a4.xml · nonDerivative · entry 1

Rawcliffe Adrian · CIK 0001555851 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,064

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on June 27, 2019 and which vested on June 27, 2020. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: These ADSs were sold in multiple transactions at a price of $9.25. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 12,288 ADSs and RSU-style options and other options covering an aggregate of 12,827,004 ordinary shares of the Issuer.

SEC source: 0001104659-20-090470 · a4.xml · nonDerivative · entry 1

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,066

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on July 2, 2018 and which vested on July 2, 2020 and from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on August 1, 2019 and which vested on August 1, 2020. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited.

F2 · security: The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F3 · price: These ADSs were sold in multiple transactions at a price of $9.25. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F4 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 8,159 ADSs and RSU-style options and other options covering an aggregate of 3,598,014 ordinary shares of the Issuer.

SEC source: 0001104659-20-090469 · a4.xml · nonDerivative · entry 1

TAYTON-MARTIN HELEN KATRINA · CIK 0001661780 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · security: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 28, 2019.

F3 · shares: The ADSs reported in this Column 4 represent solely those ADSs that were sold pursuant to a Rule 10b5-1 trading plan. Additionally, the reporting person holds 15,000 ordinary shares and share options covering an aggregate of 10,159,144 ordinary shares of the Issuer.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $8.50 to $9.34, inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

SEC source: 0001104659-20-079788 · a4.xml · derivative · entry 1

Furey John · CIK 0001691218 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 196,186

Underlying: Ordinary Shares · 196,186 shares

Expires 2030-07-01

F1 · derivative.exercise_price: The exercise price was converted from GBP1.35 based on an exchange rate of $U.S. 1.2387 to GBP1.00. The actual exercise price will be the pounds sterling amount.

SEC source: 0001104659-20-079793 · a4.xml · derivative · entry 1

Zaks Tal Zvi · CIK 0001690927 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 144,000

Underlying: Ordinary Shares · 144,000 shares

Expires 2030-07-01

F1 · derivative.exercise_price: The exercise price was converted from GBP1.35 based on an exchange rate of $U.S. 1.2387 to GBP1.00. The actual exercise price will be the pounds sterling amount.

SEC source: 0001104659-20-079782 · a4.xml · derivative · entry 1

Duncan Barbara Gayle · CIK 0001353128 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 144,000

Underlying: Ordinary Shares · 144,000 shares

Expires 2030-07-01

F1 · derivative.exercise_price: The exercise price was converted from GBP1.35 based on an exchange rate of $U.S. 1.2387 to GBP1.00. The actual exercise price will be the pounds sterling amount.

SEC source: 0001104659-20-079783 · a4.xml · derivative · entry 1

MOTT DAVID M · CIK 0001219871 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 226,753

Underlying: Ordinary Shares · 226,753 shares

Expires 2030-07-01

F1 · derivative.exercise_price: The exercise price was converted from GBP1.35 based on an exchange rate of $U.S. 1.2387 to GBP1.00. The actual exercise price will be the pounds sterling amount

SEC source: 0001104659-20-079787 · a4.xml · derivative · entry 1

Noble James · CIK 0001388000 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 179,785

Underlying: Ordinary Shares · 179,785 shares

Expires 2030-07-01

F1 · derivative.exercise_price: The exercise price was converted from GBP1.35 based on an exchange rate of $U.S. 1.2387 to GBP1.00. The actual exercise price will be the pounds sterling amount.

SEC source: 0001104659-20-079789 · a4.xml · derivative · entry 1

Alleva Lawrence M · CIK 0001553053 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 197,678

Underlying: Ordinary Shares · 197,678 shares

Expires 2030-07-01

F1 · derivative.exercise_price: The exercise price was converted from GBP1.35 based on an exchange rate of $U.S. 1.2387 to GBP1.00. The actual exercise price will be the pounds sterling amount.